[
  {
    "paper": "paper1",
    "queryType": "outcomes",
    "outcome": "",
    "http_code": "200",
    "response": {
      "outcomes": [
        "MACE",
        "myocardial infarction",
        "ischemic stroke",
        "major bleeding events",
        "intracranial bleeding",
        "all-cause mortality",
        "cardiovascular mortality"
      ]
    }
  },
  {
    "paper": "paper1",
    "queryType": "sample_sizes",
    "outcome": "",
    "http_code": "200",
    "response": {
      "error": "parse_failed",
      "raw": "{\n  \"treatment_n\": 15,480 + 9,525 + 6,270,\n  \"control_n\": 15,480 + 9,589 + 6,276,\n  \"source_quote\": \"The ASCEND trial enrolled 15,480 patients with diabetes: aspirin group 7,740 and placebo group 7,740. The ARRIVE trial had 12,546 patients: aspirin 6,270, placebo 6,276. The ASPREE trial included 19,114 participants: aspirin 9,525, placebo 9,589.\"\n}"
    }
  },
  {
    "paper": "paper1",
    "queryType": "effect_size",
    "outcome": "MACE",
    "http_code": "200",
    "response": {
      "type": "RR",
      "value": 0.87,
      "ci_lower": 0.79,
      "ci_upper": 0.96,
      "source_quote": "In patients with diabetes, aspirin reduced MACE (RR 0.87, 95% CI 0.79-0.96) with increased bleeding risk."
    }
  },
  {
    "paper": "paper1",
    "queryType": "effect_size",
    "outcome": "myocardial infarction",
    "http_code": "200",
    "response": {
      "type": "RR",
      "value": 0.82,
      "ci_lower": 0.71,
      "ci_upper": 0.94,
      "source_quote": "Aspirin significantly reduced the risk of myocardial infarction (RR 0.82, 95% CI 0.71-0.94, p=0.006, I2=27%)"
    }
  },
  {
    "paper": "paper1",
    "queryType": "events",
    "outcome": "major bleeding",
    "http_code": "200",
    "response": {
      "treatment_events": 210,
      "control_events": 0,
      "source_quote": "However, aspirin significantly increased the risk of major bleeding events (RR 1.47, 95% CI 1.31-1.65, I2=0%, number needed to harm NNH=210)"
    }
  },
  {
    "paper": "paper2",
    "queryType": "outcomes",
    "outcome": "",
    "http_code": "200",
    "response": {
      "outcomes": [
        "prevalence of hypertension",
        "prevalence of diabetes",
        "prevalence of cardiovascular disease",
        "pooled OR for hypertension",
        "pooled OR for diabetes",
        "pooled OR for cardiovascular disease",
        "OR for hypertension in Wuhan subgroup",
        "OR for hypertension in non-Wuhan subgroup",
        "OR for hypertension in younger patients",
        "publication bias for hypertension",
        "publication bias for diabetes",
        "publication bias for cardiovascular disease"
      ]
    }
  },
  {
    "paper": "paper2",
    "queryType": "sample_sizes",
    "outcome": "",
    "http_code": "200",
    "response": {
      "treatment_n": null,
      "control_n": null,
      "source_quote": "Total patients: severe group 507, non-severe group 2,779."
    }
  },
  {
    "paper": "paper2",
    "queryType": "effect_size",
    "outcome": "hypertension",
    "http_code": "200",
    "response": {
      "type": "OR",
      "value": 2.98,
      "ci_lower": 2.37,
      "ci_upper": 3.75,
      "source_quote": "Compared with non-severe patients, severe patients had a significantly higher prevalence of hypertension (pooled OR=2.98, 95% CI: 2.37-3.75, p<.001, I2=15.4%)"
    }
  },
  {
    "paper": "paper2",
    "queryType": "effect_size",
    "outcome": "diabetes",
    "http_code": "200",
    "response": {
      "type": "OR",
      "value": 2.75,
      "ci_lower": 2.09,
      "ci_upper": 3.62,
      "source_quote": "Compared with non-severe patients, severe patients had a significantly higher prevalence of diabetes (pooled OR=2.75, 95% CI: 2.09-3.62, p<.001, I2=26.1%)."
    }
  },
  {
    "paper": "paper2",
    "queryType": "effect_size",
    "outcome": "cardiovascular disease",
    "http_code": "200",
    "response": {
      "type": "OR",
      "value": 4.78,
      "ci_lower": 2.71,
      "ci_upper": 8.42,
      "source_quote": "Compared with non-severe patients, severe patients had a significantly higher prevalence of hypertension (pooled OR=2.98, 95% CI: 2.37-3.75, p<.001, I2=15.4%), diabetes (pooled OR=2.75, 95% CI: 2.09-3.62, p<.001, I2=26.1%), and cardiovascular disease (pooled OR=4.78, 95% CI: 2.71-8.42, p<.001, I2=52.5%)."
    }
  },
  {
    "paper": "paper3",
    "queryType": "sample_sizes",
    "outcome": "",
    "http_code": "200",
    "response": {
      "treatment_n": 733,
      "control_n": 946,
      "source_quote": "Treatment group total in severity cohort: severe N=733, non-severe N=4,125. For the mortality cohort: non-survivors N=213, survivors N=946."
    }
  },
  {
    "paper": "paper3",
    "queryType": "effect_size",
    "outcome": "severe COVID-19",
    "http_code": "200",
    "response": {
      "type": "OR",
      "value": 2.56,
      "ci_lower": 1.82,
      "ci_upper": 3.59,
      "source_quote": "Hypertension was also associated with severe disease (OR=2.56, 95% CI: 1.82-3.59)."
    }
  },
  {
    "paper": "paper3",
    "queryType": "effect_size",
    "outcome": "death from COVID-19",
    "http_code": "200",
    "response": {
      "type": "OR",
      "value": 11.08,
      "ci_lower": 2.59,
      "ci_upper": 47.32,
      "source_quote": "In the mortality analysis (6 studies, 1,159 patients), CVD was associated with significantly increased risk of death from COVID-19 (pooled OR=11.08, 95% CI: 2.59-47.32, p=0.001, I2=67%)."
    }
  },
  {
    "paper": "paper3",
    "queryType": "events",
    "outcome": "severe COVID-19",
    "http_code": "200",
    "response": {
      "treatment_events": 733,
      "control_events": 4125,
      "source_quote": "Treatment group total in severity cohort: severe N=733, non-severe N=4,125."
    }
  }
]
